Group 1 - The company reported the usage of previously raised funds, confirming that all funds were utilized according to the specified purposes and accounts were closed by October 2024 [2][9][11] - The total amount raised was approximately RMB 999.99 million, with a net amount of RMB 977.21 million after deducting issuance costs [1][2] - The company did not experience any changes in the investment projects funded by the raised capital [4] Group 2 - The company approved the use of raised funds to replace pre-invested self-raised funds amounting to RMB 89.66 million [5] - The investment projects funded by the previous capital raised have shown varying profitability, with the small-volume injection production base projected to generate a net profit of RMB 56.73 million in its second year and RMB 70.08 million in its third year [12] Group 3 - The company is planning to issue A-shares to specific investors, with the issuance price set at RMB 14.95 per share, which is 80% of the average trading price over the previous 20 trading days [19][20] - The total amount to be raised from this issuance is expected to be between RMB 300 million and RMB 350 million, which will be used for four investment projects and to supplement working capital [22] Group 4 - The company has faced regulatory penalties in the past five years, including a total fine of RMB 850 million for failing to disclose non-operating fund occupations and other violations [57][60] - The company has implemented corrective measures to improve internal controls and compliance with information disclosure regulations [62]
人福医药集团股份公司 前次募集资金使用情况专项报告